Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis

A Randomized, Double Blind, Parallel Group, Placebo Controlled Clinical Study of the Efficacy and Safety of Three Different Daily Dosages of Prurisol Administered Orally to Subjects With Active Mild to Moderate Chronic Plaque Psoriasis

This study is designed to evaluate the efficacy and safety of Prurisol using three different oral daily dose regimens administered to subjects with active mild to moderate chronic plaque psoriasis.

Study Overview

• Status: Completed
• Conditions: Plaque Psoriasis
• Intervention / Treatment: Drug: Prurisol; Drug: Placebo

Detailed Description

The total duration of study participation for an individual subject is approximately 112 days (16 weeks) consisting of a Screening visit, followed within 21 days by Randomization and a Treatment Period of 84 days, and a Follow-up Period of 28 days after the last day of study drug treatment. A window of ± 3 days will be considered acceptable for conduct of each scheduled visit following the first visit.

This study will require eight (8) scheduled subject visits:

x Visit 1: Screening (Up to Day 21) x Visit 2: Baseline (Day 0) x Visit 3: Day 14 Interim (± 3 days) x Visit 4: Day 28 Interim (± 3 days) x Visit 5: Day 42 Interim (± 3 days) x Visit 6: Day 56 Interim (± 3 days) x Visit 7: Day 84 End of Treatment/Unscheduled/ET (± 3 days) x Visit 8: Day 112 Follow-up (± 3 days)

• Study Type: Interventional
• Enrollment (Actual): 115
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Huntsville, Alabama, United States, 35801
      • Cellceutix Study Center
  • California
    • Encino, California, United States, 91436
      • Cellceutix Study Center
  • Florida
    • Coral Gables, Florida, United States, 33134
      • Cellceutix Study Center
    • Hialeah, Florida, United States, 33016
      • Cellceutix Study Center
    • Kissimmee, Florida, United States, 34741
      • Cellceutix Study Center
    • Miami, Florida, United States, 33126
      • Cellceutix Study Center
    • Miami, Florida, United States, 33144
      • Cellceutix Study Center
    • Pembroke Pines, Florida, United States, 33026
      • Cellceutix Study Center
  • Nevada
    • Las Vegas, Nevada, United States, 89119
      • Cellceutix Study Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or non-pregnant female adults aged 18 years with a clinical diagnosis of stable (at least 6 months) plaque psoriasis, not including scalp or intertriginous areas.

• The extent of psoriasis must meet all of the following three (3) criteria:

  • Total Body Surface Area (BSA) affected by plaque psoriasis of 10% to 20% inclusive
  • Investigator's Global Assessment (IGA) score of the severity of psoriasis of 2 or 3 (5- point ordinal scale)
  • Identification of a target psoriatic lesion with a score of 3 on the Target Lesion Assessment scale (5-point ordinal scale) for Scaling. (Other psoriatic lesions may have lower scaling scores.)
• Females of reproductive potential must not be pregnant
• Female subjects with reproductive potential, if sexually active, must agree to use reliable means of contraception
• The subject must agree to avoid prolonged exposure to the sun and avoid the use of tanning booths or other ultraviolet light sources during the study.
• The subject must provide signed and dated written informed consent to participate in the clinical study.

Exclusion Criteria:

• 1. Females of reproductive potential who are not using reliable contraception.
• Presence of any non-psoriatic uncontrolled (in the Investigator's medical opinion) systemic disease. i
• Unstable forms of psoriasis, e.g. guttate, erythrodermic, exfoliative, palmoplantar, nail, or pustular.
• Use within 6 months of biologic treatment for psoriasis
• Use within 24 months of chemotherapy or radiation therapy.
• Use within 2 months of any systemic immunosuppressive therapy.
• Use within 1 month of (1) systemic corticosteroids, (2) systemic antibiotics, (3) systemic antipsoriasis treatments (e.g. methotrexate, corticosporin, hydroxyurea), (4) PUVA therapy, (5) UVB, (6) systemic anti-inflammatory treatment.
• Use within 2 weeks of topical antipsoriasis drugs or topical corticosteroids or topical retinoids.
• Presence of a condition (e.g., history of frequent consumption of substantial quantities of alcohol, or an untreated psychiatric condition) that makes it unlikely that the requirements of the protocol will be completed.
• History of any previous use of a Tumor Necrosis Factor (TNF) blocker or other immunomodulating drug as therapy for psoriasis within the 6 months prior to screening.
• History of any allergic reaction to any formulation of abacavir.
• Previous treatment with any abacavir-containing product, e.g., Ziagen®, Epzicom®, or Trizivir®.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: 50mg of Purisol daily; One (1) 50 mg tablet of Prurisol and one (1) matching placebo tablet given AM and two (2) matching placebo tablets given PM for 84 (± 3) days	Drug: Prurisol; 50mg tablet; Other Names: Purisol, 50mg tablet
Active Comparator: 100mg of Purisol daily; One (1) 50 mg tablets of Prurisol and one (1) matching placebo tablet given twice daily (AM and PM) for 84 (± 3) days	Drug: Prurisol; 50mg tablet; Other Names: Purisol, 50mg tablet
Active Comparator: 200mg of Purisol daily; Two (2) 50 mg tablets of Prurisol given twice daily (AM and PM) for 84 (± 3) days	Drug: Prurisol; 50mg tablet; Other Names: Purisol, 50mg tablet
Placebo Comparator: Placebo daily; Two (2) placebo tablets given twice daily (AM and PM) for 84 (± 3) days	Drug: Placebo; Sugar pill designed to match Purisol tablet; Other Names: Matching Placebo to Purisol tablet

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The primary efficacy endpoint will be the percentage of subjects with ≥ 2 point improvement in IGA rating as defined by visual inspections of patient lesions	84 days

Secondary Outcome Measures

Outcome Measure	Time Frame
The Secondary efficacy endpoints are the percentage of subjects in each treatment group with:≥ 2 point improvement in IGA at 28 days	28 days
The Secondary efficacy endpoints are the percentage of subjects in each treatment group with: ≥ 2 point improvement in IGA at 56 days	56 Days
The Secondary efficacy endpoints are the percentage of subjects in each treatment group with: ≥1 point improvement in Scaling Score of Target Lesion at 28 days	28 Days
The Secondary efficacy endpoints are the percentage of subjects in each treatment group with: ≥1 point improvement in Scaling Score of Target Lesion at 56 days	56 Days
The Secondary efficacy endpoints are the percentage of subjects in each treatment group with: ≥1 point improvement in Scaling Score of Target Lesion at 84 days	84 Days

Collaborators and Investigators

• Sponsor: Cellceutix Corporation

Study record dates

Study Major Dates

• Study Start: August 1, 2015
• Primary Completion (Actual): April 1, 2016
• Study Completion (Actual): May 1, 2016

Study Registration Dates

• First Submitted: June 26, 2015
• First Submitted That Met QC Criteria: July 9, 2015
• First Posted (Estimate): July 10, 2015

Study Record Updates

• Last Update Posted (Actual): July 19, 2017
• Last Update Submitted That Met QC Criteria: July 18, 2017
• Last Verified: May 1, 2016

More Information

Terms related to this study

• Keywords: Psoriasis; Plaque Psoriasis; Topical Psoriasis; Mild Psoriasis; Moderate Psoriasis; Active Psoriasis; Skin Diseases
• Additional Relevant MeSH Terms: Skin Diseases; Skin Diseases, Papulosquamous; Psoriasis
• Other Study ID Numbers: CTIX-PRU-004

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No